19 research outputs found

    Π§ΡƒΠ²ΡΡ‚Π²ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ ΠΊ Π³Π»ΡŽΠΊΠΎΠΊΠΎΡ€Ρ‚ΠΈΠΊΠΎΡΡ‚Π΅Ρ€ΠΎΠΈΠ΄Π°ΠΌ ΠΈ Π³Π΅Ρ‚Π΅Ρ€ΠΎΠ³Π΅Π½Π½ΠΎΡΡ‚ΡŒ ΠΎΡ‚Π²Π΅Ρ‚Π° ΠΊΠ»Π΅Ρ‚ΠΎΠΊ in vitro Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с хроничСской обструктивной болСзнью Π»Π΅Π³ΠΊΠΈΡ…

    Get PDF
    Inhaled corticosteroids are widely used for the treatment of chronic obstructive pulmonary disease (COPD), but their efficacy significantly varies between patients. The aim of the study was to establish approaches to reveal steroid-sensitive and steroid-resistant patients with COPD using the blood and lung cells. Methods. Forty five patients with COPD undergoing bronchoscopy were recruited for the study of cytokine secretion by alveolar macrophages under the influence of glucocorticoids. Alveolar macrophages isolated from bronchoalveolar lavage fluid were cultured with lipopolysaccharide (LPS) and different concentrations of dexamethasone (0.01 – 1000 nM) for 24 h. Then, supernatants were removed and analyzed for concentrations of interleukin 6 (IL-6), IL-8 and tumor necrosis factor Ξ± (TNF-Ξ±). Binding of the glucocorticoid with its receptors was investigated in 24 patients with COPD, 20 healthy smokers and 20 healthy non-smokers. Blood cells were cultured with fluorescein isothiocyanate (FITC)-labelled dexamethasone and monoclonal antibodies against surface antigens of lymphocyte and monocyte populations. Fluorescence intensity of FITC-labelled dexamethasone was analyzed in blood cells using flow cytometry. Results. Dexamethasone significantly inhibited IL-6, IL-8, and TNF-Ξ± production in alveolar macrophages in a dose dependent manner. The maximal inhibition of cytokine production was observed at dexamethasone concentration of 100 nM, and the maximal cell response variability was found at 10 nM. IL-8 was less sensitive to the corticosteroid compared to IL-6 and TNF-Ξ±. Dexamethasone at any concentration failed to reach >50% inhibition of LPS-induced production of IL-8, IL-6 and TNF-Ξ± in alveolar macrophages of 40.0%; 11.1% and 8.9% of COPD patients, respectively. The fluorescence intensity of FITC-labelled dexamethasone in blood lymphocytes and monocytes was lower in smokers with COPD compared to healthy smokers and healthy non-smokers. The binding of dexamethasone with its receptors in the blood cells was higher in healthy non-smokers compared to healthy smokers. Conclusion. In vitro response of alveolar macrophages to glucocorticoids in COPD patients is characterized by significant inter-individual variability. The weak corticosteroid-related inhibition of IL-8 production can contribute to neutrophilic inflammation in COPD. The capacity of glucocorticoid receptors to bind with their ligands in blood lymphocytes and monocytes is decreased in COPD patients.Π˜Π½Π³Π°Π»ΡΡ†ΠΈΠΎΠ½Π½Ρ‹Π΅ Π³Π»ΡŽΠΊΠΎΠΊΠΎΡ€Ρ‚ΠΈΠΊΠΎΡΡ‚Π΅Ρ€ΠΎΠΈΠ΄Ρ‹ (ΠΈΠ“ΠšΠ‘) ΡˆΠΈΡ€ΠΎΠΊΠΎ ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΡƒΡŽΡ‚ΡΡ для лСчСния ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с хроничСской обструктивной болСзнью Π»Π΅Π³ΠΊΠΈΡ… (Π₯ΠžΠ‘Π›), ΠΎΠ΄Π½Π°ΠΊΠΎ ΠΈΡ… ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎ различаСтся. ЦСлью настоящСго исслСдования явилось ΠΎΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠΎΠ΄Ρ…ΠΎΠ΄ΠΎΠ² ΠΊ Π²Ρ‹ΡΠ²Π»Π΅Π½ΠΈΡŽ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с Π₯ΠžΠ‘Π›, Ρ‡ΡƒΠ²ΡΡ‚Π²ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹Ρ… ΠΈ Π½Π΅Ρ‡ΡƒΠ²ΡΡ‚Π²ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹Ρ… ΠΊ Π“ΠšΠ‘, ΠΏΡ€ΠΈ использовании ΠΊΠ»Π΅Ρ‚ΠΎΠΊ Π»Π΅Π³ΠΊΠΈΡ… ΠΈ ΠΊΡ€ΠΎΠ²ΠΈ. ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. Π’ исслСдовании Ρ†ΠΈΡ‚ΠΎΠΊΠΈΠ½-ΡΠ΅ΠΊΡ€Π΅Ρ‚ΠΈΡ€ΡƒΡŽΡ‰Π΅ΠΉ Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΈ Π°Π»ΡŒΠ²Π΅ΠΎΠ»ΡΡ€Π½Ρ‹Ρ… ΠΌΠ°ΠΊΡ€ΠΎΡ„Π°Π³ΠΎΠ² (АМ) ΠΏΠΎΠ΄ влияниСм Π“ΠšΠ‘ приняли участиС ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Ρ‹ (n = 45), ΠΊΠΎΡ‚ΠΎΡ€Ρ‹ΠΌ Π²Ρ‹ΠΏΠΎΠ»Π½ΡΠ»Π°ΡΡŒ бронхоскопия. АМ, Π²Ρ‹Π΄Π΅Π»Π΅Π½Π½Ρ‹Π΅ ΠΈΠ· Π±Ρ€ΠΎΠ½Ρ…ΠΎΠ°Π»ΡŒΠ²Π΅ΠΎΠ»ΡΡ€Π½ΠΎΠΉ Π»Π°Π²Π°ΠΆΠ½ΠΎΠΉ Тидкости, ΠΊΡƒΠ»ΡŒΡ‚ΠΈΠ²ΠΈΡ€ΠΎΠ²Π°Π»ΠΈΡΡŒ с липополисахаридом ΠΈ Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹ΠΌΠΈ концСнтрациями дСксамСтазона (0,01–1Β 000 нМ). По истСчСнии 1 суток ΡΠΎΠ±ΠΈΡ€Π°Π»ΠΈΡΡŒ супСрнатанты, Π² Π½ΠΈΡ… ΠΎΠΏΡ€Π΅Π΄Π΅Π»ΡΠ»Π°ΡΡŒ концСнтрация ΠΈΠ½Ρ‚Π΅Ρ€Π»Π΅ΠΉΠΊΠΈΠ½Π° (IL)-6, IL-8 ΠΈ Ρ„Π°ΠΊΡ‚ΠΎΡ€Π° Π½Π΅ΠΊΡ€ΠΎΠ·Π° ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ-Ξ± (TNF-Ξ±). Для изучСния особСнностСй взаимодСйствия Π“ΠšΠ‘ ΠΈ ΠΈΡ… Ρ€Π΅Ρ†Π΅ΠΏΡ‚ΠΎΡ€ΠΎΠ² обслСдованы ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Ρ‹ с Π₯ΠžΠ‘Π› (n = 24), Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹Π΅ ΠΊΡƒΡ€ΠΈΠ»ΡŒΡ‰ΠΈΠΊΠΈ (n = 20) ΠΈ Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹Π΅ нСкурящиС (n = 20). ΠšΠ»Π΅Ρ‚ΠΊΠΈ ΠΊΡ€ΠΎΠ²ΠΈ ΠΊΡƒΠ»ΡŒΡ‚ΠΈΠ²ΠΈΡ€ΠΎΠ²Π°Π»ΠΈΡΡŒ с дСксамСтазоном, ΠΌΠ΅Ρ‡Π΅Π½Π½Ρ‹ΠΌ Ρ„Π»ΡŽΠΎΡ€Π΅ΡΡ†Π΅ΠΈΠ½ΠΈΠ·ΠΎΡ‚ΠΈΠΎΡ†ΠΈΠ°Π½Π°Ρ‚ΠΎΠΌ (FITC) ΠΈ ΠΌΠΎΠ½ΠΎΠΊΠ»ΠΎΠ½Π°Π»ΡŒΠ½Ρ‹ΠΌΠΈ Π°Π½Ρ‚ΠΈΡ‚Π΅Π»Π°ΠΌΠΈ ΠΊ повСрхностным Π°Π½Ρ‚ΠΈΠ³Π΅Π½Π°ΠΌ популяций Π»ΠΈΠΌΡ„ΠΎΡ†ΠΈΡ‚ΠΎΠ² ΠΈ ΠΌΠΎΠ½ΠΎΡ†ΠΈΡ‚ΠΎΠ². Анализ интСнсивности Ρ„Π»ΡŽΠΎΡ€Π΅ΡΡ†Π΅Π½Ρ†ΠΈΠΈ FITC-ΠΌΠ΅Ρ‡Π΅Π½Π½ΠΎΠ³ΠΎ дСксамСтазона Π² ΠΊΠ»Π΅Ρ‚ΠΊΠ°Ρ… ΠΊΡ€ΠΎΠ²ΠΈ проводился с использованиСм ΠΏΡ€ΠΎΡ‚ΠΎΡ‡Π½ΠΎΠΉ Ρ†ΠΈΡ‚ΠΎΠΌΠ΅Ρ‚Ρ€ΠΈΠΈ. Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. ΠŸΡ€ΠΈ использовании дСксамСтазона дозозависимо сниТалась сСкрСция IL-6, IL-8 ΠΈ TNF-Ξ± АМ. МаксимальноС Π·Π½Π°Ρ‡Π΅Π½ΠΈΠ΅ ингибирования ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΠΈ Ρ†ΠΈΡ‚ΠΎΠΊΠΈΠ½ΠΎΠ² АМ наблюдалось ΠΏΡ€ΠΈ ΠΊΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ†ΠΈΠΈ дСксамСтазона 100 нМ, Π° наибольшая ΡΡ‚Π΅ΠΏΠ΅Π½ΡŒ Π²Π°Ρ€ΠΈΠ°Π±Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΠΈ ΠΎΡ‚Π²Π΅Ρ‚Π° ΠΊΠ»Π΅Ρ‚ΠΎΠΊ – ΠΏΡ€ΠΈ 10 нМ. IL-8 Π±Ρ‹Π» ΠΌΠ΅Π½Π΅Π΅ чувствитСлСн ΠΊ ΠΈΠ“ΠšΠ‘, Ρ‡Π΅ΠΌ IL-6 ΠΈ TNF-Ξ±. ΠŸΡ€ΠΈ любой ΠΈΠ· ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΡƒΠ΅ΠΌΡ‹Ρ… ΠΊΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ†ΠΈΠΉ дСксамСтазон Π½Π΅ ΠΈΠ½Π³ΠΈΠ±ΠΈΡ€ΠΎΠ²Π°Π» Π±ΠΎΠ»Π΅Π΅ Ρ‡Π΅ΠΌ Π½Π° 50 % ΠΈΠ½Π΄ΡƒΡ†ΠΈΡ€ΠΎΠ²Π°Π½Π½ΡƒΡŽ ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΡŽ IL-8 Π² АМ Ρƒ 40 % ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с Π₯ΠžΠ‘Π›, IL-6 – Ρƒ 11,1 %, TNF-Ξ± – Ρƒ 8,9 %. Π£ курящих ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с Π₯ΠžΠ‘Π› ΠΈΠ½Ρ‚Π΅Π½ΡΠΈΠ²Π½ΠΎΡΡ‚ΡŒ Ρ„Π»ΡŽΠΎΡ€Π΅ΡΡ†Π΅Π½Ρ†ΠΈΠΈ FITC-ΠΌΠ΅Ρ‡Π΅Π½Π½ΠΎΠ³ΠΎ дСксамСтазона Π² популяциях Π»ΠΈΠΌΡ„ΠΎΡ†ΠΈΡ‚ΠΎΠ² ΠΈ ΠΌΠΎΠ½ΠΎΡ†ΠΈΡ‚Π°Ρ… ΠΊΡ€ΠΎΠ²ΠΈ оказалась Π½ΠΈΠΆΠ΅, Ρ‡Π΅ΠΌ Ρƒ курящих ΠΈ нСкурящих Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹Ρ…. БвязываниС дСксамСтазона со своими Ρ€Π΅Ρ†Π΅ΠΏΡ‚ΠΎΡ€Π°ΠΌΠΈ Π² ΠΊΠ»Π΅Ρ‚ΠΊΠ°Ρ… ΠΊΡ€ΠΎΠ²ΠΈ Π±Ρ‹Π»ΠΎ Π²Ρ‹ΡˆΠ΅ Ρƒ нСкурящих Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹Ρ…, Ρ‡Π΅ΠΌ Ρƒ Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹Ρ… ΠΊΡƒΡ€ΠΈΠ»ΡŒΡ‰ΠΈΠΊΠΎΠ². Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. Π₯ΠžΠ‘Π› характСризуСтся сущСствСнной ΠΌΠ΅ΠΆΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡƒΠ°Π»ΡŒΠ½ΠΎΠΉ Π²Π°Ρ€ΠΈΠ°Π±Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΡŒΡŽ in vitro ΠΎΡ‚Π²Π΅Ρ‚Π° АМ Π½Π° Π“ΠšΠ‘. ΠžΠ³Ρ€Π°Π½ΠΈΡ‡Π΅Π½Π½ΠΎΠ΅ ΠΈΠ½Π³ΠΈΠ±ΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠ΅ синтСза IL-8 Π“ΠšΠ‘ ΠΌΠΎΠΆΠ΅Ρ‚ ΡΠΏΠΎΡΠΎΠ±ΡΡ‚Π²ΠΎΠ²Π°Ρ‚ΡŒ ΠΏΠΎΠ΄Π΄Π΅Ρ€ΠΆΠ°Π½ΠΈΡŽ Π½Π΅ΠΉΡ‚Ρ€ΠΎΡ„ΠΈΠ»ΡŒΠ½ΠΎΠ³ΠΎ Ρ‚ΠΈΠΏΠ° воспалСния ΠΏΡ€ΠΈ Π₯ΠžΠ‘Π›. Для ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с Π₯ΠžΠ‘Π› свойствСнно сниТСниС способности Π“ΠšΠ‘-Ρ€Π΅Ρ†Π΅ΠΏΡ‚ΠΎΡ€ΠΎΠ² ΡΠ²ΡΠ·Ρ‹Π²Π°Ρ‚ΡŒΡΡ со своими Π»ΠΈΠ³Π°Π½Π΄Π°ΠΌΠΈ Π² Π»ΠΈΠΌΡ„ΠΎΡ†ΠΈΡ‚Π°Ρ… ΠΈ ΠΌΠΎΠ½ΠΎΡ†ΠΈΡ‚Π°Ρ… ΠΊΡ€ΠΎΠ²ΠΈ

    OPEN XAL Status Report 2015

    Get PDF
    MOPW1050International audienceOpen XAL is an accelerator physics software platformdeveloped in collaboration among several facilitiesaround the world. The Open XAL collaboration wasformed in 2010 to port, improve and extend the successfulXAL platform used at the Spallation Neutron Source foruse in the broader accelerator community and to establishit as the standard platform for accelerator physicssoftware. The site-independent core is complete, activeapplications have been ported, and now we are in theprocess of verification and transitioning to using OpenXAL in production. This paper will present the currentstatus and a roadmap for this project

    Open XAL status Report 2015

    Get PDF
    Open XAL is an accelerator physics software platform developed in collaboration among several facilities around the world. The Open XAL collaboration was formed in 2010 to port, improve and extend the successful XAL platform used at the Spallation Neutron Source for use in the broader accelerator community and to establish it as the standard platform for accelerator physics software. The site-independent core is complete, active applications have been ported, and now we are in the process of verification and transitioning to using Open XAL in production. This paper will present the current status and a roadmap for this project

    ΠΠ›Π›ΠžΠ’Π ΠΠΠ‘ΠŸΠ›ΠΠΠ’ΠΠ¦Π˜Π― ΠΠ’Πž-ΠΠ•Π‘ΠžΠ’ΠœΠ•Π‘Π’Π˜ΠœΠ«Π₯ ΠŸΠžΠ§Π•Πš Π£ Π”Π•Π’Π•Π™

    Get PDF
    At present the problem of donor organs for transplantation shortage remains unsolved. Cautious and mixed attitude towards the transplantation of incompatible kidneys remains, while it could considerably reduce the donor organ waiting time for a recipient. Experience of 19 allotransplantations of ABO-incompatible kidneys in children is analyzed in the article. A group of 14 patients who received ABOcompatible kidneys was chosen for the comparative analysis. Such parameters as the assessment of function of allotransplanted kidneys, morphology character comparison of biopsy materials of allo-kidneys in both groups, actuarial survival rate of the recipients with functioning allografts are used to assess the results. Comparison of the aforementioned parameters showed practically the same results, and that enables us to assert that transplantations of kidneys of ABO-incompatible donors have the right to exist.Π’ настоящСС врСмя остаСтся Π½Π΅Ρ€Π΅ΡˆΠ΅Π½Π½ΠΎΠΉ ΠΏΡ€ΠΎΠ±Π»Π΅ΠΌΠ° Π½Π΅Ρ…Π²Π°Ρ‚ΠΊΠΈ донорских ΠΎΡ€Π³Π°Π½ΠΎΠ² для трансплантации. БохраняСтся настороТСнноС, Π½Π΅ΠΎΠ΄Π½ΠΎΠ·Π½Π°Ρ‡Π½ΠΎΠ΅ ΠΎΡ‚Π½ΠΎΡˆΠ΅Π½ΠΈΠ΅ ΠΊ пСрСсадкС нСсовмСстимых ΠΏΠΎΡ‡Π΅ΠΊ, ΠΏΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Ρ… ΠΌΠΎΠ³Π»ΠΎ Π±Ρ‹ Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎ ΡΠΎΠΊΡ€Π°Ρ‚ΠΈΡ‚ΡŒ врСмя оТидания Ρ€Π΅Ρ†ΠΈΠΏΠΈΠ΅Π½Ρ‚ΠΎΠΌ донорского ΠΎΡ€Π³Π°Π½Π°. Π’ ΡΡ‚Π°Ρ‚ΡŒΠ΅ ΠΏΡ€ΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π½ ΠΎΠΏΡ‹Ρ‚ 19 аллотрансплантаций АВ0-нСсовмСстимых ΠΏΠΎΡ‡Π΅ΠΊ Ρƒ Π΄Π΅Ρ‚Π΅ΠΉ. Для ΡΡ€Π°Π²Π½ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° Π²Ρ‹Π±Ρ€Π°Π½Π° Π³Ρ€ΡƒΠΏΠΏΠ° ΠΈΠ· 14 Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ…, ΠΊΠΎΡ‚ΠΎΡ€Ρ‹ΠΌ Π²Ρ‹ΠΏΠΎΠ»Π½Π΅Π½Ρ‹ пСрСсадки АВ0-совмСстимых ΠΏΠΎΡ‡Π΅ΠΊ. Для ΠΎΡ†Π΅Π½ΠΊΠΈ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚ΠΎΠ² ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΠΎΠ²Π°Π½Ρ‹ Ρ‚Π°ΠΊΠΈΠ΅ ΠΏΠ°Ρ€Π°ΠΌΠ΅Ρ‚Ρ€Ρ‹, ΠΊΠ°ΠΊ ΠΎΡ†Π΅Π½ΠΊΠ° Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΈ аллотрансплантированных ΠΏΠΎΡ‡Π΅ΠΊ, сравнСниС Ρ…Π°Ρ€Π°ΠΊΡ‚Π΅Ρ€Π° ΠΌΠΎΡ€Ρ„ΠΎΠ»ΠΎΠ³ΠΈΠΈ Π±ΠΈΠΎΠΏΡ‚Π°Ρ‚ΠΎΠ² Π°Π»Π»ΠΎΠΏΠΎΡ‡Π΅ΠΊ Π² ΠΎΠ±Π΅ΠΈΡ… Π³Ρ€ΡƒΠΏΠΏΠ°Ρ…, ΠΎΡ†Π΅Π½ΠΊΠ° Π°ΠΊΡ‚ΡƒΠ°Ρ€Π½ΠΎΠΉ выТиваСмости Ρ€Π΅Ρ†ΠΈΠΏΠΈΠ΅Π½Ρ‚ΠΎΠ² с Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΎΠ½ΠΈΡ€ΡƒΡŽΡ‰ΠΈΠΌΠΈ аллотрансплантатами. Π‘Ρ€Π°Π²Π½Π΅Π½ΠΈΠ΅ Π²Ρ‹ΡˆΠ΅ΠΏΠ΅Ρ€Π΅Ρ‡ΠΈΡΠ»Π΅Π½Π½Ρ‹Ρ… ΠΏΠ°Ρ€Π°ΠΌΠ΅Ρ‚Ρ€ΠΎΠ² ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΎ практичСски ΠΎΠ΄ΠΈΠ½Π°ΠΊΠΎΠ²Ρ‹Π΅ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹, Ρ‡Ρ‚ΠΎ Π΄Π°Π΅Ρ‚ Π½Π°ΠΌ ΠΏΡ€Π°Π²ΠΎ ΡƒΡ‚Π²Π΅Ρ€ΠΆΠ΄Π°Ρ‚ΡŒ: пСрСсадки ΠΏΠΎΡ‡Π΅ΠΊ ΠΎΡ‚ АВ0-нСсовмСстимых Π΄ΠΎΠ½ΠΎΡ€ΠΎΠ² ΠΈΠΌΠ΅ΡŽΡ‚ ΠΏΡ€Π°Π²ΠΎ Π½Π° сущСствованиС

    Anemia in renal allograft recipients

    Get PDF
    The review deals with anemia, one of the posttransplantation complications. To define the ways of preventing this complication in the posttransplantation period, the factors favors its development are analyzed. Anemia is shown to negatively affect autografted kidney function and actuarial survival in allokidney graft recipients. The current principles in the treatment of posttransplantation anemia are reflected

    Generation of donor-specific immunotolerance in renal-allograft recipients

    Get PDF
    The kidney cannot be successfully grafted without immunosuppressive therapy. A unicenter retrospective study has evaluated the efficiency of immunosuppression with daclizumab (Zenapax) versus alemtuzumab (Campath).Subjects and methods. After renal allotransplantation, 64 patients, including 34 and 30 patients, were treated with daclizumab and alemtuzumab, respectively. The absolute count of peripheral blood lymphocytes was measured. Renal grafts were morphologically assessed as described by Banff.Results. After administration of alemtuzumab, there was a more pronounced decrease in the absolute count of peripheral blood lymphocytes and the rate of acute rejection crisis was 1.5 times lower than that after use of daclizumab.Conclusion. During the study, alemtuzumab demonstrated a more marked immunosuppressive activity than did daclizumab and the ability of the former to generate donor-specific immunotolerance in renal-allograft recipients

    Laser-assisted H

    No full text
    corecore